ES2739546T3 - Compuestos de fenotiazina para tratar el deterioro cognitivo leve - Google Patents

Compuestos de fenotiazina para tratar el deterioro cognitivo leve Download PDF

Info

Publication number
ES2739546T3
ES2739546T3 ES08762390T ES08762390T ES2739546T3 ES 2739546 T3 ES2739546 T3 ES 2739546T3 ES 08762390 T ES08762390 T ES 08762390T ES 08762390 T ES08762390 T ES 08762390T ES 2739546 T3 ES2739546 T3 ES 2739546T3
Authority
ES
Spain
Prior art keywords
unsubstituted
substituted
alkyl
aliphatic
carboaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08762390T
Other languages
English (en)
Spanish (es)
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Application granted granted Critical
Publication of ES2739546T3 publication Critical patent/ES2739546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08762390T 2007-06-19 2008-06-17 Compuestos de fenotiazina para tratar el deterioro cognitivo leve Active ES2739546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
ES2739546T3 true ES2739546T3 (es) 2020-01-31

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08762390T Active ES2739546T3 (es) 2007-06-19 2008-06-17 Compuestos de fenotiazina para tratar el deterioro cognitivo leve

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
EP3686181B1 (en) * 2013-01-30 2024-07-17 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) * 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
DK2853293T3 (en) * 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
MY162313A (en) * 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds

Also Published As

Publication number Publication date
HUE045460T2 (hu) 2019-12-30
HRP20191513T1 (hr) 2019-11-29
JP5725605B2 (ja) 2015-05-27
US9211294B2 (en) 2015-12-15
SI2167095T1 (sl) 2019-09-30
MY177001A (en) 2020-09-01
PL2167095T3 (pl) 2019-11-29
DK2167095T3 (da) 2019-07-29
CN101820884B (zh) 2013-08-28
EP2167095B1 (en) 2019-05-29
JP2010530403A (ja) 2010-09-09
WO2008155533A2 (en) 2008-12-24
CA2690746A1 (en) 2008-12-24
WO2008155533A3 (en) 2009-02-19
AU2008265045B2 (en) 2014-02-27
PT2167095T (pt) 2019-08-06
CN101820884A (zh) 2010-09-01
AU2008265045A1 (en) 2008-12-24
EP2167095A2 (en) 2010-03-31
US20100184752A1 (en) 2010-07-22
CA2690746C (en) 2018-01-02
BRPI0813670A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
AU2008265045B2 (en) Phenothiazine compounds for treating Mild Cognitive Impairment
ES2675544T3 (es) Tratamiento para trastornos mentales y neurológicos
ES2701089T3 (es) Uso terapéutico de las diaminofenotiazinas
ES2881081T3 (es) Procedimientos y composiciones para mejorar la función cognitiva
ES2948263T3 (es) Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil
ES2952672T3 (es) Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia
ES2886873T3 (es) Composiciones farmacéuticas para mejorar el rendimiento de la memoria
US20230310488A1 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
BR112020016672A2 (pt) Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo
US20110217387A1 (en) Pharmaceutical composition for treatment of fibromyalgia
ITRM960360A1 (it) Farmaco a base di un derivato della carnitina per il trattamento del= la demenza di alzheimer in pazienti ad insorgenza precoce della pato=
ES2949288T3 (es) Uso de un inhibidor de acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con enfermedad de Parkinson
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
CN114072154B (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
ES2747993T3 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
EP4587008A1 (en) Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine
ES2355393T3 (es) Memantina para el tratamiento de la enfermedad de alzehimer de leve a moderada.
ES2340399T3 (es) Uso de neboglamina para el tratamiento de la esquizofrenia.
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
CA3034187A1 (en) Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
BRPI1015509A2 (pt) Tratamento da dor aguda, não traumática, utilizando uma combinação de diclofenaco-colestiramina, uridina, citidina e hidroxocobalamina